JP2020518649A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518649A5
JP2020518649A5 JP2019561224A JP2019561224A JP2020518649A5 JP 2020518649 A5 JP2020518649 A5 JP 2020518649A5 JP 2019561224 A JP2019561224 A JP 2019561224A JP 2019561224 A JP2019561224 A JP 2019561224A JP 2020518649 A5 JP2020518649 A5 JP 2020518649A5
Authority
JP
Japan
Prior art keywords
tetrahydro
cyclopropa
pentalene
diaza
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019561224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518649A (ja
JP7247106B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031688 external-priority patent/WO2018208848A1/en
Publication of JP2020518649A publication Critical patent/JP2020518649A/ja
Publication of JP2020518649A5 publication Critical patent/JP2020518649A5/ja
Application granted granted Critical
Publication of JP7247106B2 publication Critical patent/JP7247106B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019561224A 2017-05-08 2018-05-08 内臓痛の治療のための化合物および方法 Active JP7247106B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762503280P 2017-05-08 2017-05-08
US62/503,280 2017-05-08
PCT/US2018/031688 WO2018208848A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treatment of visceral pain

Publications (3)

Publication Number Publication Date
JP2020518649A JP2020518649A (ja) 2020-06-25
JP2020518649A5 true JP2020518649A5 (enExample) 2021-07-26
JP7247106B2 JP7247106B2 (ja) 2023-03-28

Family

ID=62245468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019561224A Active JP7247106B2 (ja) 2017-05-08 2018-05-08 内臓痛の治療のための化合物および方法

Country Status (13)

Country Link
US (2) US20200078358A1 (enExample)
EP (1) EP3621619B1 (enExample)
JP (1) JP7247106B2 (enExample)
KR (1) KR20200005614A (enExample)
CN (1) CN110709085A (enExample)
AU (1) AU2018266145A1 (enExample)
BR (1) BR112019023214A2 (enExample)
CA (1) CA3062824A1 (enExample)
EA (1) EA201992638A1 (enExample)
ES (1) ES2956059T3 (enExample)
MA (1) MA48625A (enExample)
MX (2) MX2019013311A (enExample)
WO (1) WO2018208848A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019013311A (es) 2017-05-08 2020-08-03 Arena Pharm Inc Compuestos y metodos para el tratamiento del dolor visceral.
WO2023059610A1 (en) * 2021-10-05 2023-04-13 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators
WO2023150648A2 (en) * 2022-02-02 2023-08-10 Makscientific, Llc Pharmaceutical compositions, and preparation and methods of use thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605906A (en) 1995-03-24 1997-02-25 Merck Frosst Canada, Inc. Cannabinoid receptor agonists
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5971080A (en) 1997-11-26 1999-10-26 Central Sprinkler Corporation Quick response dry pipe sprinkler system
US7308894B2 (en) 1998-06-03 2007-12-18 Scott Laboratories, Inc. Apparatuses and methods for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures according to appropriate clinical heuristics
CN101070316A (zh) 1999-04-28 2007-11-14 萨诺费－阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
IL150302A (en) 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
ITMI20041033A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
CA2586011C (en) 2004-07-12 2011-07-19 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
FR2875230A1 (fr) 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
PL1902034T3 (pl) 2005-06-02 2011-09-30 Glenmark Pharmaceuticals Sa Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
US7597910B2 (en) 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
CA2623803A1 (en) 2005-09-23 2007-03-29 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
SI2081572T1 (sl) 2006-07-04 2010-06-30 Janssen Pharmaceutica Nv Benzimidazolni kanabinoidni agonisti ki nosijo substituirano heterociklično skupino
EA200900403A1 (ru) 2006-09-25 2009-10-30 Бёрингер Ингельхайм Интернациональ Гмбх Соединения, которые модулируют рецептор св2
WO2008063781A2 (en) 2006-10-12 2008-05-29 Abbott Laboratories Chemical compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
US20080200501A1 (en) 2006-11-03 2008-08-21 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
US9763894B2 (en) 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
US20090325936A1 (en) 2006-12-20 2009-12-31 Bilodeau Mark T Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080161340A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof
WO2008109007A1 (en) 2007-03-02 2008-09-12 Cara Therapeutics, Inc. Bridged phenanthridines
EP2142531B1 (en) 2007-03-30 2015-07-08 Janssen Pharmaceutica N.V. Benzimidazole cannabinoid agonists
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
JP5485148B2 (ja) 2007-06-21 2014-05-07 カラ セラピューティクス インコーポレイテッド 置換イミダゾ複素環
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
CA2749884C (en) 2009-01-28 2018-01-23 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN102596913B (zh) 2009-08-28 2016-11-09 艾尼纳制药公司 大麻素受体调节剂
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
JP6043733B2 (ja) * 2011-02-25 2016-12-14 アリーナ ファーマシューティカルズ， インコーポレイテッド カンナビノイド受容体モジュレーター
WO2012116277A1 (en) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
EA035989B1 (ru) * 2011-02-25 2020-09-09 Арена Фармасьютикалз, Инк. Кристаллические формы и способы получения модуляторов каннабиноидного рецептора
WO2016085941A1 (en) 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
US20180252736A1 (en) 2015-09-01 2018-09-06 Arena Pharmaceuticals, Inc. Cb2 receptor internalization
EA201892280A1 (ru) 2016-04-10 2019-04-30 Арена Фармасьютикалз, Инк. Способы лечения селективными агонистами cb-рецептора
WO2018208847A1 (en) * 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
MX2019013311A (es) 2017-05-08 2020-08-03 Arena Pharm Inc Compuestos y metodos para el tratamiento del dolor visceral.
WO2019056123A1 (en) * 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
US20240165109A1 (en) * 2021-03-02 2024-05-23 Arena Pharmaceuticals, Inc. Methods of Treatment with Selective CB2 Receptor Agonists
WO2023059610A1 (en) * 2021-10-05 2023-04-13 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators

Similar Documents

Publication Publication Date Title
ES2391382T3 (es) Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
AU2012255935B2 (en) Compounds for use in treatment of mucositis
JP7028765B2 (ja) ベンズアミドおよび活性化合物組成物および使用方法
BR112013001553A2 (pt) Métodos e compostos para tratar infecções por vírus paramyxoviridae
KR20200080254A (ko) 혈액학적 장애를 치료하기 위한 화합물 및 조성물
BR112017005111B1 (pt) Compostos análogos de nucleotídeo acíclico, composição farmacêutica contendo tais compostos, e usos da composição no tratamento de uma infecção por papilomavírus
JP2020532539A (ja) 抗癌剤としての環状ジヌクレオチド
EA034872B1 (ru) Комбинация ингибитора mek кобиметиниба и ингибитора erk (s)-1-(1-(4-хлор-3-фторфенил)-2-гидроксиэтил)-4-(2-((1-метил-1h-пиразол-5-ил)амино)пиримидин-4-ил)пиридин-2(1h)-она для применения в лечении раковых заболеваний
TW201938149A (zh) 用於治療癌症的選擇性組蛋白去乙醯酶3 (hdac3)抑制劑及免疫治療劑之組合
WO2017101791A1 (zh) 化合物及其在制备药物中的用途
JP2020518649A5 (enExample)
CN118974089A (zh) 基于pd-1抑制剂和sik3抑制剂的组合疗法
JP2022522312A (ja) ピロール化合物
US20240390399A1 (en) Materials and methods for suppressing and/or treating bone related diseases and symptoms
ES2945062T3 (es) Derivados de ácido barbitúrico novedosos, su preparación y uso de los mismos como inhibidores de la transmigración de leucocitos y para el tratamiento de enfermedades inflamatorias, enfermedades autoinmunitarias y cáncer
US20160229857A1 (en) Substituted pyrrolo[2,3-d]dipyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
US11254662B2 (en) 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof
KR20090025247A (ko) 방사선 치료 증강제
JP2017137323A (ja) 新規抗がん剤
JP2020518649A (ja) 内臓痛の治療のための化合物および方法
WO1992011247A1 (fr) Composition anticancereuse et compose
KR20250026146A (ko) 붕소 화합물의 전구약물 및 박테리아 감염 치료에 있어서의 이의 용도
PT2699240E (pt) Derivados da acadesina, produtos e composições compreendendo os mesmos, suas utilizações terapêuticas e seus processos de síntese
JP2003238414A (ja) 医薬組成物
CA3102434A1 (en) Selective a2a receptor antagonist